Circulating KIM-1 and survival outcomes in renal cell carcinoma: A systematic review and meta-analysis.
Jiafu Lu, Bo Luo, Chao Xue et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the prognostic significance of circulating kidney injury molecule-1 (KIM-1) in renal cell carcinoma (RCC) across 2,415 patients from 7 studies. Elevated KIM-1 levels were significantly associated with worse overall survival (HR = 1.70, 95% CI: 1.22-2.35), progression-free survival (HR = 1.34, 95% CI: 1.05-1.72), and disease-free survival (HR = 1.72, 95% CI: 1.45-2.04).
Key findings
- Elevated KIM-1 levels were associated with worse overall survival (HR = 1.70, 95% CI: 1.22-2.35).
- KIM-1 was linked to worse progression-free survival (HR = 1.34, 95% CI: 1.05-1.72).
- Worse disease-free survival was associated with elevated KIM-1 (HR = 1.72, 95% CI: 1.45-2.04).
- Prognostic effects were consistent across localized and advanced disease settings.
Why it matters
The findings suggest that circulating KIM-1 could serve as a valuable biomarker for risk stratification in RCC, potentially guiding treatment decisions and patient management strategies.
What to keep in mind
The study noted heterogeneity among included cohorts and emphasized the need for further prospective validation.